Navigation Links
Matrix Corporate Capital and PharmaVentures Announce the Signing of a Memorandum of Understanding (MOU)

LONDON and OXFORD, England, March 15, 2010 /PRNewswire/ -- Matrix Corporate Capital ("Matrix") and PharmaVentures Limited ("PharmaVentures") today announced the signing of a Memorandum of Understanding ("MOU") covering strategic transactions in the biotech, pharmaceutical and med tech sectors. The companies will work together to identify licensing, buyout, investment, IPO and consolidation opportunities which bring together both strategic expertise and capital from Europe's dedicated healthcare investors.

The MOU joins two firms with synergistic transactional capabilities in the healthcare life sciences space:

Matrix is a provider of a full range of corporate finance services to small and mid cap growth companies. They are able to service companies across the full corporate lifecycle, with access to financing from Series A venture finance through IPO, secondary placements and traded debt.

PharmaVentures is a leading specialist healthcare business advisory group assisting corporations in all aspects of strategic transactions, from strategy formulations to implementation. PharmaVentures has an extensive track record of successful strategic advisory mandates in the sector with over 17 years of experience and 450 assignments, for over 600 clients, in 38 countries.

Fintan Walton, Chief Executive of PharmaVentures said "For our clients our alliance with Matrix will create one of Europe's strongest teams in healthcare transactions and equity financing. Our clients have always demanded the best and a strong experienced healthcare team is essential to their own success. Matrix has excellent proven capabilities in corporate finance and we are delighted to have entered into this agreement."

Malcolm Le May, Chief Executive of Matrix Corporate Capital said "We are delighted to team our skills with those of PharmaVentures. It has an excellent track record with some of the largest names in the pharmaceutical sector. Many of these companies now face unprecedented change in their business models, with the pursuit of greater efficiency driving buyouts; assets sales and licensing. Matrix has access to both private and public sector-specific capital across Europe which, with PharmaVentures' help, will allow us to create innovative transactions around these assets."

About Matrix Group

Matrix Corporate Capital is part of Matrix Group which is a privately owned financial services business founded in 1987 other areas of expertise include Asset Management, Property, and Specialised Finance.To date Matrix has raised around GBP8 billion for its investment products and currently has circa GBP3 billion of funds under management. Matrix's staff of over 200 are based in the West End of London at One Vine Street. Matrix Group Limited is the holding company for the following business activities

About PharmaVentures

PharmaVentures Limited (http://www.pharmaventures.con) is based in Oxford, England and is a leading international corporate advisory firm supporting its clients' growth ambitions through licensing, joint ventures and M&A in the healthcare industry. The company works for a variety of clients from start-ups to global pharmaceutical corporations, their advisors, investment companies and government bodies. It also produces the highly popular PharmaDeals(R) range of intelligence products including analysis tools and reports. In 2006 it launched the world's first dedicated online pharmaceutical television channel PharmaTelevision(R) (


    Matrix Corporate Capital LLP
    Steve Cox, Partner

    PharmaVentures Limited
    Tibor Papp

SOURCE PharmaVentures Limited & Matrix Corporate Capital

Back to top
SOURCE PharmaVentures Limited & Matrix Corporate Capital
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. NeoMatrix Announces Additional Funding for Breakthrough Breast Cancer Screening Test
2. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
3. BioNanomatrix Receives New NCI Grant to Support Development of Chip-Based Nanofluidics Systems for Cell Fractionation
4. BioNanomatrix and Complete Genomics Receive $8.8 Million NIST-ATP Award to Develop Sequencing Platform for $100 Genome
5. TEI Biosciences Launches SurgiMend(TM) Collagen Matrix for Soft Tissue Reconstruction
6. Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications
7. Biosensors Receives CE Mark Approval for Its BioMatrix(R) Drug-Eluting Coronary Stent System
8. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
9. Organogenesis, Inc. Announces Acquisition of NanoMatrix, Inc.
10. Engineers make first active matrix display using nanowires
11. BioNanomatrix Named Best Management Team at the 2008 Ben Franklin Emerging Business Awards
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015 Orexigen® Therapeutics, ... will participate in a fireside chat discussion at the ... New York . The discussion is scheduled for ... .  A replay will be available ... Contact:McDavid Stilwell  , Julie NormartVP, Corporate Communications and ...
(Date:11/24/2015)... Nov. 24, 2015  Asia-Pacific (APAC) holds the ... (CRO) market. The trend of outsourcing to low-cost ... but higher volume share for the region in ... however, margins in the CRO industry will improve. ... ( ), finds that the market ...
(Date:11/24/2015)... Halozyme Therapeutics, Inc. (NASDAQ: HALO ) will be ... York on Wednesday, December 2 at 9:30 a.m. ET/6:30 ... CEO, will provide a corporate overview. th Annual ... 1:00 p.m. ET/10:00 a.m. PT . Jim Mazzola , ... corporate overview. --> th Annual Oppenheimer Healthcare Conference ...
(Date:11/24/2015)... Florida (PRWEB) , ... November 24, 2015 , ... ... biggest event of the year and one of the premier annual events for ... and ran from 8–11 November 2015, where ISPE hosted the largest number of ...
Breaking Biology Technology:
(Date:11/18/2015)... new scientific discoveries deepen our understanding of how cancer ... challenges in better using that knowledge to guide treatment ... children continue to survive pediatric cancer, that counseling may ... John M. Maris, M.D ., a pediatric oncologist ... --> John M. Maris, M.D ., ...
(Date:11/17/2015)... , Nov. 17, 2015  Vigilant Solutions announces today ... its Board of Directors. --> ... recently retiring from the partnership at TPG Capital, one ... with over $140 Billion in revenue.  He founded and ... all the TPG companies, from 1997 to 2013.  In ...
(Date:11/12/2015)... 2015  Arxspan has entered into an agreement ... for use of its ArxLab cloud-based suite of ... partnership will support the institute,s efforts to electronically ... information internally and with external collaborators. The ArxLab ... the Institute,s electronic laboratory notebook, compound and assay ...
Breaking Biology News(10 mins):